InvestorsHub Logo
Followers 231
Posts 34993
Boards Moderated 1
Alias Born 11/19/2003

Re: None

Monday, 10/13/2014 9:29:48 AM

Monday, October 13, 2014 9:29:48 AM

Post# of 536
Barclays Initiates Foamix Pharmaceuticals At Overweight - Foamix

Analysts at Barclays initiated coverage on shares of Foamix Pharmaceuticals (NASDAQ: FOMX) with a Overweight rating.

The target price for Foamix Pharmaceuticals is set to $11.

Foamix Pharmaceuticals' shares fell 3.61% to close at $5.08 on Friday

Pharmaceuticals (NASDAQ:FOMX) | Benzinga
http://www.benzinga.com/analyst-ratings/initiation/14/10/4916444/barclays-initiates-foamix-pharmaceuticals-at-overweight

It may not be much money, but it's mine dammit to hell, not 'yours'.